Developers are trying to meet abundant demand for biomanufacturing space as growing biopharmaceutical firms advance new medicines toward production. But building facilities for the fledgling industry takes a strong stomach.
More biopharma are seeking to place their drug production in their own backyard, which, in research-heavy markets like Boston, San Francisco and San Diego, means developers have to find scarce greenfield sites or convert older industrial properties. Beyond the inherent logistical challenges and long delivery times of manufacturing development, rapidly evolving science and the unproven tenants clamoring for space add up to a high-risk environment.
Image: Bisnow/Andrew Martinez Outshine Properties' Bill Hunter speaks as CRISPR Therapeutics' Denis Desmond listens at a Bisnow event Oct. 21, 2021.
